According to our recent payer coverage analysis for HGH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access by channel shows how payer pharmacy benefits cover HGH products. Over the past quarter, health exchange and medicare lives became more restricted. Utilization management is also evolving, with more PAs in place.
Source: MMIT data as of Q1 2018
Trends: See how long-acting product formulation market events, biobetters and new payer coverage strategies are shifting this landscape.
To read the full Reality Check on human growth hormones with key findings on clinical characteristics, HGH drug market access and payer coverage, please click on the button below: